Galanthamine Hydrobromide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317963

CAS#: 1953-04-4 (HBr); 1953-04-4 (free base).

Description: Galantamine Hydrobromide is the hydrobromide salt form of galantamine, a tertiary alkaloid with anticholinesterase and neurocognitive-enhancing activities. It is an alkaloid acetylcholinesterase inhibitor. Galantamine competitively and reversibly inhibits acetylcholinesterase, thereby increasing the concentration and enhancing the action of acetylcholine (Ach). This agent may improve neurocognitive function in mild and moderate Alzheimer' s disease and may reduce abstinence-induced cognitive symptoms that promote smoking relapse.

Chemical Structure

Galanthamine Hydrobromide
CAS# 1953-04-4 (HBr); 1953-04-4 (free base).

Theoretical Analysis

MedKoo Cat#: 317963
Name: Galanthamine Hydrobromide
CAS#: 1953-04-4 (HBr); 1953-04-4 (free base).
Chemical Formula: C17H22BrNO3
Exact Mass:
Molecular Weight: 368.27
Elemental Analysis: C, 55.44; H, 6.02; Br, 21.70; N, 3.80; O, 13.03

Price and Availability

Size Price Availability Quantity
25.0mg USD 180.0 2 Weeks
50.0mg USD 250.0 2 Weeks
100.0mg USD 350.0 2 Weeks
200.0mg USD 450.0 2 Weeks
500.0mg USD 650.0 2 Weeks
1.0g USD 850.0 2 Weeks
2.0g USD 1450.0 2 Weeks
Bulk inquiry

Synonym: Galanthamine Hydrobromide; Galantamine HBr; Nivalin; Razadyne; Reminyl; Nivaline; Razadyne.

IUPAC/Chemical Name: (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide


InChi Code: InChI=1S/C17H21NO3.BrH/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17;/h3-6,12,14,19H,7-10H2,1-2H3;1H/t12-,14-,17-;/m0./s1

SMILES Code: CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 368.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Li W, Zhou Y, Zhao N, Hao B, Wang X, Kong P. Pharmacokinetic behavior and
efficiency of acetylcholinesterase inhibition in rat brain after intranasal
administration of galanthamine hydrobromide loaded flexible liposomes. Environ
Toxicol Pharmacol. 2012 Sep;34(2):272-9. doi: 10.1016/j.etap.2012.04.012. Epub
2012 May 3. PubMed PMID: 22613079.

2: Riemann D, Gann H, Dressing H, Müller WE, Aldenhoff JB. Influence of the
cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry
Res. 1994 Mar;51(3):253-67. PubMed PMID: 8208872.

3: Yamboliev I, Mutafova-Yambolieva V, Mihailova D. Gastrointestinal loss of
galanthamine hydrobromide in rats in-situ. J Pharm Pharmacol. 1993
Aug;45(8):763-5. PubMed PMID: 7901379.

4: Snorrason E, Stefánsson JG. Galanthamine hydrobromide in mania. Lancet. 1991
Mar 2;337(8740):557. PubMed PMID: 1671920.

5: Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J, Jovovich V. Pharmacokinetics
of galanthamine hydrobromide after single subcutaneous and oral dosage in humans.
Pharmacology. 1989;39(1):50-8. PubMed PMID: 2587617.

6: Mihailova D, Velkov M, Zhivkova Z. In vitro metabolism of galanthamine
hydrobromide (Nivalin) by rat and rabbit liver homogenate. Eur J Drug Metab
Pharmacokinet. 1987 Jan-Mar;12(1):25-30. PubMed PMID: 3609070.

7: Mihailova D, Yamboliev I. Pharmacokinetics of galanthamine hydrobromide
(Nivalin) following single intravenous and oral administration in rats.
Pharmacology. 1986;32(6):301-6. PubMed PMID: 3725886.

8: Cozanitis D, Dessypris A, Nuuttila K. The effect of galanthamine hydrobromide
on plasma ACTH in patients undergoing anaesthesia and surgery. Acta Anaesthesiol
Scand. 1980 Jun;24(3):166-8. PubMed PMID: 6255718.

9: Cozanitis DA. [Galanthamine hydrobromide : a substitute for eserine sulphate
(physostigmine) in the treatment of the cerebral effects of anti-cholinergic
substances]. Nouv Presse Med. 1978 Dec;7(45):4152. French. PubMed PMID: 745952.

10: Cozanitis DA. Galanthamine hydrobromide, a longer acting anticholinesterase
drug, in the treatment of the central effects of scopolamine (Hyoscine).
Anaesthesist. 1977 Dec;26(12):649-50. PubMed PMID: 603022.

11: Cozanitis DA, Toivakka E. Treatment of respiratory depression with the
anticholinesterase drug galanthamine hydrobromide. Anaesthesia. 1974
Sep;29(5):581-4. PubMed PMID: 4433018.

12: Cozanitis DA, Rosenberg P. Preliminary experiments with galanthamine
hydrobromide on depressed respiration. Anaesthesist. 1974 Jul;23(7):302-5. PubMed
PMID: 4458502.

13: Cozanitis DA. Galanthamine hydrobromide versus neostigmine. A plasma cortisol
study in man. Anaesthesia. 1974 Mar;29(2):163-8. PubMed PMID: 4819071.

14: Cozanitis DA, Nuuttila K, Karhunen P, Baraka A. Changes in cardiac rhythm
with galanthamine hydrobromide. Anaesthesist. 1973 Oct;22(10):457-9. PubMed PMID:

15: Cozanitis D, Toivakka E, Dessypris A. Electroencephalographic and blood
chemistry responses to galanthamine hydrobromide in epileptic volunteers.
Anaesthesist. 1973 Jan;22(1):31-3. PubMed PMID: 4632556.

16: Cozanitis DA, Halttunen P, Edgren J. A cinebronchographic study demonstrating
the effect of galanthamine hydrobromide on conscious asthmatic volunteers.
Anaesthesist. 1972 Feb;21(2):63-6. PubMed PMID: 5027567.

17: Pereira MA, Pena AA, Cardoso A, Freitas MJ, Ferro FN. [Galanthamine
hydrobromide in the reversion of nondepolarizing neuromuscular block]. Rev Bras
Anestesiol. 1972 Jan-Mar;22(1):10-9. Portuguese. PubMed PMID: 4261779.

18: Cozanitis DA, Toivakka E. A comparative study of galanthamine hydrobromide
and atropine-neostigmine in conscious volunteers. Anaesthesist. 1971
Nov;20(11):416-21. PubMed PMID: 5126442.

19: Cozanitis DA. Experiences with galanthamine hydrobromide as curare
antagonist. Anaesthesist. 1971 Jun;20(6):226-9. PubMed PMID: 4256926.

20: Costantini D, Josi G, Signore L. [Clinical and electrocardiographic tests of
the use of galanthamine hydrobromide as a de-curarizing drug]. Acta Anaesthesiol.
1971 Jan-Feb;22(1):75-83. Italian. PubMed PMID: 5109626.